Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Liabilities and Shareholders Equity (2023 - 2025)

Immunome's Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $683.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 184.38% year-over-year to $683.2 million; the TTM value through Dec 2025 reached $1.6 billion, up 45.68%, while the annual FY2025 figure was $683.2 million, 184.38% up from the prior year.
  • Liabilities and Shareholders Equity reached $683.2 million in Q4 2025 per IMNM's latest filing, up from $299.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $683.2 million in Q4 2025 to a low of $41.4 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $255.5 million, with a median of $276.6 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 614.89% in 2024, then rose 0.03% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $148.5 million in 2023, then soared by 61.73% to $240.2 million in 2024, then surged by 184.38% to $683.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Liabilities and Shareholders Equity are $683.2 million (Q4 2025), $299.4 million (Q3 2025), and $296.3 million (Q2 2025).